Chien-nien Chen

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

KLF6 activation marks an angiogenic and apoptosis resistant endothelial phenotype in pulmonary arterial hypertension.

KLF6 activation marks an angiogenic and apoptosis resistant endothelial phenotype in pulmonary arterial hypertension.

Journal: Communications biology

Published: February 07, 2025

ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension.

ARF6 as a Novel Activator of HIF-2α in Pulmonary Arterial Hypertension.

Journal: American journal of respiratory cell and molecular biology

Published: November 18, 2024

Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.

Early Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.

Journal: Infectious disease reports

Published: October 24, 2024

Deep phenotyping the right ventricle to establish translational MRI biomarkers for characterization of adaptive and maladaptive states in pulmonary hypertension.

Deep phenotyping the right ventricle to establish translational MRI biomarkers for characterization of adaptive and maladaptive states in pulmonary hypertension.

Journal: Scientific reports

Published: August 20, 2024

Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology.

Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology.

Journal: American journal of respiratory and critical care medicine

Published: September 07, 2023

SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.

SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.

Journal: Circulation

Published: April 17, 2023

TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.

TLR7/8 activation induces autoimmune vasculopathy and causes severe pulmonary arterial hypertension.

Journal: The European respiratory journal

Published: February 03, 2023

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.

Journal: Scientific reports

Published: January 18, 2020

The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia.

The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia.

Journal: Nature

Published: December 05, 2014

Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.

Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.

Journal: Circulation

Published: May 22, 2013

Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension.

Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension.

Journal: Vascular pharmacology

Published: July 06, 2012

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.

Journal: Circulation

Published: June 20, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026